Related Experiment Videos
[Hormonal replacement therapy and cardiovascular risk: contra-indication or non-indication?]
1Service de cardiologie A, hôpital de La Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France. georges.chiche@wanadoo.fr
Gynecologie, Obstetrique & Fertilite
|October 18, 2003
Summary
Hormonal replacement therapy (HRT) is not recommended for cardiovascular risk reduction in postmenopausal women. Recent studies confirm that HRT does not offer cardioprotection and guidelines now prohibit its use in women with coronary conditions.
Area of Science:
- Cardiovascular disease
- Menopause management
- Hormonal replacement therapy
Context:
- Observational studies previously suggested cardioprotective benefits of hormonal replacement therapy (HRT).
- The Heart and Estrogen/Progestin Replacement Study (HERS) challenged the established dogma of HRT's cardioprotective effects.
- Many observational studies overlooked crucial socio-economic factors in their analyses.
Purpose:
- To re-evaluate the role of hormonal replacement therapy (HRT) in cardiovascular risk and treatment for postmenopausal women.
- To synthesize evidence from randomized controlled trials following the HERS publication.
- To provide updated guidance for prescribers regarding HRT use in menopause.
Summary:
- Multiple randomized trials, excluding EPAT, have failed to demonstrate cardiovascular benefits of HRT.
- The findings contradict earlier beliefs based on observational data.
- Current evidence strongly advises caution and discourages HRT for cardiovascular prevention in postmenopausal women.
Impact:
- Current guidelines formally prohibit the use of HRT in women with coronary heart disease.
- HRT is also prohibited for primary prevention of chronic conditions in healthy postmenopausal women.
- This shift in understanding necessitates a reevaluation of menopausal hormone therapy strategies.